MoST-LLy Study

The Molecular Screening and Therapeutics in leukemia and lymphoma (MoST-LLy) study is a national clinical initiative aimed at improving treatment outcomes for patients with blood cancers.

MoST-LLy is looking at new ways to test blood cancers using advanced genetic and molecular testing. The goal is to learn more about each person's cancer and see whether this information can help identify treatment options that may be suitable for them.

The MoST-LLy study is a haematology extension of the MoST program.

Process:

1. Referral from a Haematologist (blood cancer doctor)

2. Eligibility for the MoSTLLy study reviewed by the MoSTLLy(QIMR) study team

3. Participant reviews and signs MoSTLLy Participant Information and Consent Form if interested in participating

4. A suitable blood cancer sample is requested/collected and prepared for testing

5. The sample undergoes detailed genetic and molecular testing

6. A team of experts reviews the results and prepares a report to be sent to the referring haematologist

7. The referring haematologist discusses the results and any potential treatment options with the patient

8. The study team may contact the treating haematologist later to obtain follow-up information (current treatments)

If a patient agrees to participate in the study, their blood cancer sample may be tested using one or more advanced methods, including gene panel testing, whole exome sequencing (WES), whole genome sequencing (WGS), or whole transcriptome sequencing (WTS). These tests look for changes in the cancer that may help doctors better understand the disease and identify treatments that could be beneficial.

After testing, a report is sent to the referring haematologist that includes:

(i) Important genetic or molecular changes identified in the cancer.

(ii) Potential treatment options that may be suitable for the patient, including clinical trials, targeted therapies, or other personalised treatment approaches.

The ethical aspects of this study have been approved by the HREC of Metro South Health EC00167 (HREC/2024/QMS/113451).

This study is made possible through the support of the Leukaemia Foundation of Australia, Tour de Cure and an MRFF Grant with CIA Prof Steven Lane.

Want to learn more?

Patients and families can download the MoST-LLy General Information Sheet, which provides an overview of the study, how molecular testing is performed, who may be suitable, and contact details for the study team.

Download the MoST-LLy study General Information Sheet (Version 4)

Who is suitable for the MoST-LLy Program?

The MoST-LLy study is for people aged 18 years and older with a blood cancer who meet the study eligibility requirements.

How can a patient enrol in the MoST-LLy Program?

The MoST-LLy study is available nationally through the QIMR Berghofer remote consenting hub.

Patients interested in the study should discuss participation with their haematologist. The haematologist can assess eligibility and, where appropriate, refer the patient to the study using a secure online referral form.

Eligible patients will be contacted by the study team to discuss participation and complete the consent process.

For Referring Haematologists

Clinicians can access the online referral form below. The referral portal contains additional information regarding study requirements, patient eligibility criteria, required documentation, and the referral process.

Online Referral Form

• patients with blood cancer of any type
• patients aged 18 years and over